Home>>Peptides>>Influenza Hemagglutinin (HA) Peptide

Influenza Hemagglutinin (HA) Peptide (Synonyms: H-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-OH)

Catalog No.GP10152

A peptide

Products are for research use only. Not for human use. We do not sell to patients.

Influenza Hemagglutinin (HA) Peptide Chemical Structure

Cas No.: 92000-76-5

Size Price Stock Qty
10mM (in 1mL DMSO)
$140.00
In stock
5mg
$75.00
In stock
25mg
$311.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Product Documents

Quality Control & SDS

View current batch:

Background

HA tag,Complexes containing plasmid DNA, transferrin-polylysine conjugates, and polylysine-conjugated peptides derived from the N-terminal sequence of the influenza virus hemagglutinin subunit HA-2 have been used for the transfer of luciferase or -galactosidase marker genes to K562 cells, HeLa cells, and BNL CL.2 hepatocytes. The presence of these influenza peptide conjugates in the DNA complexes renders the complexes active in membrane disruption in a liposome leakage assay and results in a substantial augmentation of the transferrin-polylysine-mediated gene transfer.
Fusogenic peptides derived from the N-terminal sequence of the influenza virus hemagglutinin subunit HA-2 is part of the DNA complexes and the resulting augmentation of gene transfer to cultured cells1.
In the influenza virus, the hemagglutinin (HA) protein mediates both binding of the virus to the cell surface and the subsequent fusion of viral and cellular membranes. HA is composed of a receptor-binding subunit, denoted HA1, and a fusogenic subunit, denoted HA2. The native HA1yHA2 complex, as found on the surface of the native virus, is fusioninactive. For influenza virus, membrane fusion is regulated by the conformational state of the hemagglutinin (HA) protein, which switches from a native (nonfusogenic) structure to a fusion-active (fusogenic) conformation when exposed to the acidic environment of the cellular endosome. The native structure of HA is trapped in a metastable state and that the fusogenic conformation is released by destabilization of native structure2.

References:
1. E. WAGNER, C. PLANK et al, Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle. Proc. Nati. Acad. Sci. USA Vol. 89, pp. 7934-7938, September 1992
2. C. M. CARR, C. CHAUDHRY, P. S. KIM et al. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14306–14313

Chemical Properties

Cas No. 92000-76-5 SDF
Synonyms H-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-OH
Chemical Name Influenza Hemagglutinin (HA) Peptide
Canonical SMILES CC(C)C(C(=O)N1CCCC1C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(C)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)N
Formula C53H67N9O17 M.Wt 1102.15
Solubility ≥55.1075mg/mL in DMSO, ≥100.4 mg/mL in EtOH, ≥46.2 mg/mL in Water Storage Desiccate at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 0.9073 mL 4.5366 mL 9.0732 mL
5 mM 0.1815 mL 0.9073 mL 1.8146 mL
10 mM 0.0907 mL 0.4537 mL 0.9073 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for Influenza Hemagglutinin (HA) Peptide

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Influenza Hemagglutinin (HA) Peptide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.